TY - JOUR T1 - Estimating RSV seasonality from pandemic disruptions: a modelling study JF - medRxiv DO - 10.1101/2022.06.18.22276591 SP - 2022.06.18.22276591 AU - Fabienne Krauer AU - Tor Erlend Fjelde AU - Mihaly Koltai AU - David Hodgson AU - Marina Treskova-Schwarzbach AU - Christine Harvey AU - Mark Jit AU - Ole Wichmann AU - Thomas Harder AU - Stefan Flasche Y1 - 2022/01/01 UR - http://medrxiv.org/content/early/2022/06/19/2022.06.18.22276591.abstract N2 - Background Respiratory syncytial virus (RSV) is a leading cause of respiratory tract infections and bronchiolitis in young children. The seasonal pattern of RSV is shaped by short-lived immunity, seasonally varying contact rates and pathogen viability. The magnitude of each of these parameters is not fully clear. The disruption of the regular seasonality of RSV during the COVID pandemic in 2020 due to control measures, and the ensuing delayed surge in RSV cases provides an opportunity to disentangle these factors and to understand the implication for vaccination strategies. A better understanding of the drivers of RSV seasonality is key for developing future vaccination strategies.Methods We developed a mathematical model of RSV transmission, which simulates the sequential re-infection (SEIRRS4) and uses a flexible Von Mises function to model the seasonal forcing. Using MCMC we fit the model to laboratory confirmed RSV data from 2010-2022 from NSW while accounting for the reduced contact rates during the pandemic with Google mobility data. We estimated the baseline transmission rate, its amplitude and shape during RSV season as well as the duration of immunity. The resulting parameter estimates were compared to a fit to pre-pandemic data only, and to a fit with a cosine forcing function. We then simulated the expected shifts in peak timing and amplitude under two vaccination strategies: continuous and seasonal vaccination.Results We estimate that RSV dynamics in NSW can be best explained by a high effective baseline transmission rate (2.94/d, 95% CrI 2.72-3.19) and a narrow peak with a maximum 13% increase compared to the baseline transmission rate. We also estimate the duration of post infection temporary but sterilizing immunity to be 412 days (95% CrI 391-434). A cosine forcing resulted in a similar fit and posterior estimates. Excluding the data from the pandemic period in the fit increased parameter correlation and yielded less informative posterior distributions. The continuous vaccination strategy led to more extreme seasonal incidence with a delay in the peak timing and a higher amplitude whereas seasonal vaccination flattened the incidence curves.Conclusion Quantifying the parameters that govern RSV seasonality is key in determining potential indirect effects from immunization strategies as those are being rolled out in the next few years.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFK: Innovation Fund of the Joint Federal Committee (grant no. 01VSF18015), Wellcome Trust (grant no. 221303/Z/20/Z). TEF: PhD funding received from Huawei Technologies Research & Development (UK) Ltd. MK: Innovation Fund of the Joint Federal Committee (grant no. 01VSF18015). DH: National Institutes of Health (1R01AI141534-01A1). MJ: European Union's Horizon 2020 research and innovation programme SC1-PHE-CORONAVIRUS-2020 - project EpiPose (No 101003688), the NIHR HPRU in Modelling and Health Economics (grant code HPRU-2019-NIHR200908) and the NIHR HPRU in Immunisation (grant code HPRU-2019-NIHR200929). SF: Wellcome Trust (grant no. 208812/Z/17/Z). The views expressed are those of the authors and not necessarily those of the United Kingdom (UK) Department of Health and Social Care, the National Health Service, the National Institute for Health Research (NIHR), the UK Health Security Agency or any other funder. The European Commission is not responsible for any use that may be made of the information it contains.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe R/Julia code as well as all input and output data are available in a Github repository (https://github.com/fkrauer/RSV-seasonality-public). The original RSV case notification data are available on the MSW MoH website [27,28]. The Google mobility data were downloaded from [30]. https://github.com/fkrauer/RSV-seasonality-public ER -